Summit Therapeutics (SMMT) Total Current Liabilities (2018 - 2026)

Summit Therapeutics (SMMT) has reported Total Current Liabilities for 9 consecutive years, with $103.6 million the latest figure, recorded in Q2 2026.

• Quarterly Total Current Liabilities rose 71.68% year-over-year to $103.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $103.6 million (up 71.68% YoY) and the FY2025 annual result came in at $73.0 million, up 74.91% from the prior year.
• Total Current Liabilities improved to $103.6 million in Q2 2026 per SMMT's latest filing, from $83.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for SMMT reached as high as $140.2 million in Q2 2024 and fell as low as $11.9 million in Q2 2023.
• A 5-year average of $52.3 million and a median of $40.3 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 68.89% — and 2024, when it surged 1074.82%.
• Year by year, Total Current Liabilities stood at $38.8 million in 2022, then slumped by 47.39% to $20.4 million in 2023, then surged by 104.5% to $41.7 million in 2024, then soared by 74.91% to $73.0 million in 2025, then jumped by 41.89% to $103.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $103.6 million, $83.3 million, and $73.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.